Teva Pharmaceutical Industries (TEVA) Finished Goods (2010 - 2018)

Teva Pharmaceutical Industries (TEVA) has reported Finished Goods for 9 consecutive years, with $2.7 billion the latest figure, recorded in Q4 2018.

• Quarterly Finished Goods fell 0.89% year-over-year to $2.7 billion in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $2.7 billion (down 0.89% YoY) and the FY2018 annual result came in at $2.7 billion, down 0.89% from the prior year.
• Finished Goods retreated to $2.7 billion in Q4 2018 per TEVA's latest filing, from $2.7 billion in the prior quarter.
• Over the last five years, Finished Goods for TEVA reached as high as $2.9 billion in Q2 2017 and fell as low as $2.0 billion in Q1 2016.
• A 5-year average of $2.5 billion and a median of $2.6 billion in 2014 frame the typical range for Finished Goods.
• Annual changes were most pronounced in 2015 — Finished Goods decreased 16.08% — and 2017, when it soared 43.01%.
• Year by year, Finished Goods stood at $2.3 billion in 2014, then dropped by 9.61% to $2.1 billion in 2015, then soared by 38.15% to $2.8 billion in 2016, then slipped by 5.05% to $2.7 billion in 2017, then dropped by 0.89% to $2.7 billion in 2018.
• According to Business Quant data, Finished Goods over the past three periods registered $2.7 billion, $2.7 billion, and $2.7 billion for Q4 2018, Q3 2018, and Q2 2018 respectively.